Boston Scientific Corporation $BSX Holdings Lowered by Artisan Partners Limited Partnership

Artisan Partners Limited Partnership reduced its holdings in Boston Scientific Corporation (NYSE:BSX) by 44.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,756,162 shares of the medical equipment provider’s stock after selling 3,762,039 shares during the quarter. Artisan Partners Limited Partnership owned 0.32% of Boston Scientific worth $464,344,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of BSX. Steph & Co. purchased a new stake in shares of Boston Scientific during the 3rd quarter worth about $25,000. Financial Consulate Inc. bought a new position in Boston Scientific during the third quarter valued at approximately $25,000. Murphy & Mullick Capital Management Corp increased its stake in shares of Boston Scientific by 200.0% during the 3rd quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock worth $25,000 after purchasing an additional 170 shares during the last quarter. FWL Investment Management LLC bought a new position in Boston Scientific during the second quarter valued at about $26,000. Finally, United Community Bank lifted its position in shares of Boston Scientific by 115.7% in the third quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock worth $27,000 after buying an additional 147 shares during the last quarter. 89.07% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on BSX. Citigroup decreased their target price on shares of Boston Scientific from $130.00 to $102.00 and set a “buy” rating on the stock in a research report on Thursday, February 5th. JPMorgan Chase & Co. dropped their target price on Boston Scientific from $135.00 to $100.00 and set an “overweight” rating for the company in a report on Thursday, February 5th. Morgan Stanley cut their target price on Boston Scientific from $130.00 to $118.00 and set an “overweight” rating for the company in a research report on Thursday, February 5th. Truist Financial lowered their price target on Boston Scientific from $120.00 to $95.00 and set a “buy” rating on the stock in a research report on Thursday, February 5th. Finally, The Goldman Sachs Group set a $99.00 price objective on Boston Scientific in a research note on Thursday, February 5th. One analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $108.36.

Insiders Place Their Bets

In other Boston Scientific news, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $101.55, for a total value of $1,758,135.15. Following the completion of the sale, the executive vice president owned 23,600 shares in the company, valued at $2,396,580. The trade was a 42.32% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Michael F. Mahoney sold 160,901 shares of the firm’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total value of $15,042,634.49. Following the transaction, the chief executive officer owned 1,411,735 shares in the company, valued at approximately $131,983,105.15. This trade represents a 10.23% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 0.50% of the company’s stock.

Boston Scientific Price Performance

Boston Scientific stock opened at $75.77 on Friday. The company has a current ratio of 1.62, a quick ratio of 1.08 and a debt-to-equity ratio of 0.46. The firm has a market capitalization of $112.43 billion, a P/E ratio of 39.06, a PEG ratio of 1.02 and a beta of 0.67. The business has a 50-day moving average of $87.69 and a 200-day moving average of $95.83. Boston Scientific Corporation has a 1 year low of $72.69 and a 1 year high of $109.50.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, topping the consensus estimate of $0.78 by $0.02. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The firm had revenue of $5.29 billion for the quarter, compared to analyst estimates of $5.29 billion. During the same period in the previous year, the company posted $0.70 earnings per share. The company’s revenue for the quarter was up 15.9% on a year-over-year basis. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. On average, equities analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current year.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.